fezolinetant · Astellas · NDA 216578
Veozah
Earliest generic entry, as listed
28 Mar 2034
Blocked by patent: US 10836768, US 9422299, US 9987274.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10836768 | use U-3622 | 28 Mar 2034 |
| US 9422299 | substance, product, use U-3622 | 28 Mar 2034 |
| US 9987274 | use U-3622 | 28 Mar 2034 |
| US 8871761 | substance | 4 Apr 2031 |
Exclusivities · 1 unexpired
| NCE | new chemical entity (5 years) | 12 May 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 216578 · 001 · RLD | tablet, oral | 45MG | 28 Mar 2034 |